Mandate

Vinge advises Norwegian Property ASA in connection with the sale of Norgani Hotels AS

November 08, 2010

Vinge has advised Norwegian Property ASA a company listed on the Oslo Stock Exchange in connection with the sale of Norgani Hotels AS to Sech Holding AB, a company owned by Pandox AB and Heches Holding AB, which, in turn, are controlled by Eiendomsspar AS and the Sundt family. Completion took place on 4 November and the purchase price amounted to approximately SEK 9.9 billion. Norgani Hotels AS conducts hotel ownership and management operations in the Nordic countries. The real estate portfolio consists of 73 hotels, 41 of which are located in Sweden. Following the acquisition, Pandox AB will be one of the leading hotel property owners in Europe with 119 hotels.

Vinge’s team consisted of partners Morgan Hallén and Fredrik Sonander and several associates including Christina Carrick.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024